Search

International audience

National audience

National audience

par l'Organisation Mondiale de la santé (WHO); International audience; Over recent years, management of Buruli ulcer patients has considerably changed with advances in antibiotherapy. Antibiotherapy is particularly effective on nonulcerative forms. However, the bacteriological diagnosis in the early forms is difficult because simple and non-invasive methods are not available. In this study, the diagnostic effectiveness of the Fine Needle aspiration was evaluated on early lesions. Our results showed that PCR from FNA samples, unlike Ziehl-Neelsen staining, is very sensitive on nonulcerative forms like other standard sampling methods (biopsy and punch biopsy). Furthermore, mycolactone was detected in aspirated liquid from lesions in mouse experimentally infected by M. ulcerans and in FNA from Buruli ulcer patients. This is a crucial observation to encourage the development of diagnosis test based on mycolactone detection. Moreover, mycolactone was never detected in aspirated liquid from a patient treated by antibiotherapy. To conclude, fine needle aspiration is a simple, fast, painless, accurate and inexpensive method of sampling and could be used for diagnosis of M. ulcerans infection.

Résumé publié dans : Fundamental & Clinical Pharmacology, avril 2010, 24(Suppl. 1): p. 55-56. doi:10.1111/j.1472-8206.2010.00819.x; National audience; Introduction: Secnidazole is an anti infective agent which belongs to the 5-nitroimidazole class.Method: The objective of the trial was to characterize the pharmacokinetics of secnidazole after oral administration of a 2g dose, as microgranules formulation in healthy subjects. Blood samples were collected before, 1, 2, 3, 6, 9, 12, 24, 36, 48, 72, 96, 120, 168 and 240 h after dosing. Urines were collected in 24-h-fractions for the first five days and in 48 h-fraction for the last sample. The cumulative urinary excretion was captured for each subject from urine concentration (lg/L). Pharmacokinetic parameters were obtained by a non-compartmental approach (WinNonlin Pharsight). The assay was performed by ultra-performance liquid chromatography coupled with mass spectrometry detection (UPLC-MS/MS, Quattro Premier, Waters) after simple protein precipitation of 50 lL plasma sample. Chromatographic separation was done on a C18 Acquity column (50 mm · 2.1 mm, id 1.7 lm, Waters), in isocratic mode (80% water/0.1% formic acid and 20% acetonitrile). Ornidazole was used as internal standard. The detection was operated in positive mode and multiple reaction monitoring was used for quantification (186 > 128 ion transition for secnidazole). The lower limit of quantification was 10 and 100 lg/L for plasma and urine samples respectively.Results: Sixteen subjects (8 female, 8 male) were included. Population characteristics such as: age ranged from 23 to 50 years (mean ± SD: 38 ± 9.2 years), weight ranged from 51 to 90 Kg (mean ± SD = 64.6 ± 10.1 Kg) and body mass index (BMI) ranged from 19.9 to 24.2 Kg/m 2 (mean ± SD = 21.9 ± 1.5 Kg/m 2 ;). Secnidazole exposure achieved a maximal concentration (Cmax) with a mean of 37.9 ± 8.5 mg/L (range 20–56 mg/L) and at a median time associated with the Cmax (Tmax) of 6 h (range 3–6 h). The area under the curve to the last measurable time (AUC0_t) and the total area under the curve (AUC0_¥) were 1281.9 ± 416.4 mg h/L and 1304.2 ± 444.1 mg h/L (mean ± SD) respectively.The Cl/F and V/F were 1.7 ± 0.5 L/h and 40.2 ± 9.2 L respectively and the elimination half-life (t1/2) was 17.5 ± 4.3 h (mean ± SD). The mean amount of secnidazole excreted in the 168-h urine collection was 310.47 mg (15.5% of the administered dose). For example, for the subject number 5, the observed parameters are: Cmax 37.3 mg/L, Tmax 3 h, AUC0_¥ 1029.5 mg h/L and t1/2 15.6 h.Conclusion: After a 2 g single oral dose, secnidazole presents a good absorption profile and relatively long elimination half life ensuring probable sufficient exposure with once a day administration.